Clinical Trial Opens for New Generation Proteasome Inhibitor

Dr. Ola Landgren announced the opening of a new Phase I/II clinical trial at Memorial Sloan-Kettering Cancer Center for patients with relapsed and/or refractory myeloma. The trial will test a new proteasome inhibitor called VLX1570, which is given intravenously. VLX1570 was developed by researchers at Sweden's Karolinska Institute. Memorial Sloan-Kettering has some funds available to help patients who demonstrate financial need with transportation and hotel costs. Click HERE to see the full trial listing. Please call the IMF InfoLine at [phone] with any further questions.

Source: International Myeloma Foundation - July 11, 2015 Category: Hematology Source Type: news